Neovacs S.A - 0LW

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune and inflammatory diseases, and various types of cancer in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company’s product pipeline comprises IFNa-Kinoid, an anti-interferon alpha therapeutic vaccine for the treatment of lupus; and TNF-Kinoid, an anti-TNF immunotherapy for rheumatoid arthritis and Crohn’s disease. It is also developing VEGF-Kinoid for the treatment of age-related macular degeneration and solid tumors; and IL4-Kinoid for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.